- Home
- » Tags
- » Fulvestrant
Top View
- National PBM Drug Monograph Fulvestrant (Faslodex®) January
- October 1, 2019
- Brand Generic Guide
- Construction of a TF–Mirna–Gene Feed-Forward Loop Network
- Fulvestrant As a Reference Antiestrogen and Estrogen Receptor
- Appendix F9. University of Maryland Health Partners (UMHP) Prescription Drugs Subject to Nqtls, by Delivery System
- Ibrance (Palbociclib) Annual Review Date: 04/15/2021
- Fulvestrant in Postmenopausal Women with Advanced Breast Cancer
- Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies
- Examples of Prohibited and Permitted Substances And
- Hormonal Therapy
- Preliminary Experience with Pure Antiestrogens 1
- Fulvestrant: Pharmacokinetics and Pharmacology
- Faslodex (Fulvestrant)
- Faslodex, INN-Fulvestrant
- Importance of Selective Estrogen Receptor Modulators As Potential
- Examples of Prohibited Substances & Methods
- Fulvestrant ('Faslodex')
- Assessment Report for Faslodex (Fulvestrant)
- An Oestrogen Receptor Antagonist with a Novel Mechanism of Action
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- WADA 2018 Prohibited List
- Sulfation of Afimoxifene, Endoxifen, Raloxifene, and Fulvestrant by the Human Cytosolic Sulfotransferases
- List Item Fulvestrant Mylan
- Recommendations from York and Scarborough Medicines
- CVS Caremark® Value Formulary Effective As of 07/01/2021
- Use of Fulvestrant in the Treatment of Resistant
- Real-World Data of Fulvestrant As First-Line Treatment Of
- State Mac List Office of Medical Assistance Programs
- Hazardous Medicines
- FASLODEX® (Fulvestrant) Injection, for Intramuscular Use Dose for Patients with Moderate Hepatic Impairment
- Fulvestrant for the Treatment of Advanced Breast Cancer in Postmenopausal Women: a Japanese Study
- Paragraph IV Patent Certifications (PPIV)
- 2020 Prohibited List
- Year of FDA Monthly Cost Approval
- Estrone Sulfate Transport and Steroid Sulfatase Activity in Colorectal Cancer
- Estrone Sulfate Transport and Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone Replacement Therapy
- Faslodex, INN-Fulvestrant
- (12) Patent Application Publication (10) Pub. No.: US 2017/0224970 A1 MUNSTER Et Al
- Faslodex, INN-Fulvestrant
- Faslodex, INN-Fulvestrant
- Endocrine Manipulation in Advanced Breast Cancer: Recent Advances with SERM Therapies
- FASLODEX (Fulvestrant)
- Hazardous Drug List
- Prospective Assessment of the Endometrium in Postmenopausal
- European Patent Office
- Fulvestrant Formulation
- Endocrine Therapy for Advanced Breast Cancer Payal D
- Estrogen Sulfotransferase (SULT1E1): Its Molecular Regulation, Polymorphisms, and Clinical Perspectives